Semaglutide vs Tirzepatide
Which GLP-1 is more effective for you? This tool compares the average weight loss percentages of Semaglutide (GLP-1) and Tirzepatide (GLP-1 + GIP) based on clinical trial averages.
Your current weight
How many weeks of treatment you are projecting
What is the primary difference between Semaglutide and Tirzepatide?
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist, targeting a single hormone to reduce appetite and slow gastric emptying. Tirzepatide (Mounjaro/Zepbound) is a "dual agonist," targeting both GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors. This dual action is believed to lead to greater weight loss and better glucose control in many patients.
Which medication is more effective for weight loss?
Clinical trials generally show that Tirzepatide (Zepbound/Mounjaro) leads to a higher percentage of total body weight loss compared to Semaglutide (Wegovy/Ozempic). In the SURMOUNT trials, Tirzepatide users often achieved 15-22% weight loss, while the STEP trials for Semaglutide typically showed 10-15%. However, individual responses vary, and some patients tolerate one better than the other.
Do they have different side effect profiles?
Both cause similar gastrointestinal side effects (nausea, vomiting, diarrhea). Some studies suggest that Tirzepatide may have a slightly different side effect profile due to the GIP component, though the "peak" nausea during titration is common to both. The risk of pancreatitis and gallbladder issues is similar across the GLP-1 class.
Can you switch from one to the other?
Yes, many patients switch medications if they plateau on one or experience intolerable side effects. This typically requires a new titration period, as the dosing scales are completely different (e.g., moving from a 2.4mg Wegovy dose to a 2.5mg Mounjaro starting dose). Always consult a physician for a cross-over protocol.